肺炎球菌结合疫苗引入后的间接(群体)保护:系统文献综述
该系统综述检索PubMed 2000年1月至2016年2月的英文文献,纳入评价5岁以上人群肺炎球菌疾病率的研究。49篇文献显示,多数国家在儿童国家免疫规划引入肺炎球菌结合疫苗后,成人侵袭性肺炎球菌疾病和肺炎发病率下降或变化不显著,少数报告显著上升;间接效应似乎取决于疫苗覆盖率和全国实施时间,65岁以上成人似乎获益最大。
要点
- 多数国家儿童国家免疫规划引入肺炎球菌结合疫苗后,成人侵袭性肺炎球菌疾病和肺炎发病率下降或变化不显著。
- 少数研究报告肺炎球菌疾病率显著上升,主要来自肺炎球菌结合疫苗覆盖率低和/或监测不充分的国家。
- 对老年人群的间接效应似乎取决于肺炎球菌结合疫苗覆盖率和全国实施时间,65岁以上成人似乎获益最大。
核心结论
- 多数国家在儿童国家免疫规划引入肺炎球菌结合疫苗后,成人侵袭性肺炎球菌疾病和肺炎发病率下降。
- 对老年人群的间接效应似乎取决于肺炎球菌结合疫苗覆盖率和全国实施时间。
- 65岁以上成人似乎从肺炎球菌结合疫苗引入中获益最大。
研究设计与样本
- 系统文献综述,检索PubMed数据库,限定英文文献,发表时间为2000年1月至2016年2月。
- 纳入评价5岁以上人群肺炎球菌疾病率的研究,由两位作者独立提取文献。
- 检索词包括肺炎球菌结合疫苗、群体、间接、成人和肺炎。
主要发现
- 共纳入49篇符合选择标准的文献,其中39篇关于侵袭性肺炎球菌疾病(其中1篇仅关于脑膜炎),8篇关于肺炎,2篇同时涉及侵袭性肺炎球菌疾病和肺炎。
- 多数报告来自美国、英国和加拿大,数据来源、质量和完整性存在相当大的变异性。
- 大多数研究报告成人在全国实施肺炎球菌结合疫苗后侵袭性肺炎球菌疾病和肺炎疾病率出现统计学显著下降或无统计学显著变化。
- 少数研究报告肺炎球菌疾病率统计学显著上升,主要来自肺炎球菌结合疫苗覆盖率低和/或监测不充分的国家。
临床怎么用
- 原文未据此给出推荐。
局限性
- 数据来源、质量和完整性存在相当大的变异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcal diseases are major causes of morbidity among adults, especially those over 50years of age. While pneumococcal conjugated vaccines (PCV's) impact on pneumococcal disease rates among children is well established, the extent of its impact on adult pneumococcal related illness remains unclear. The aim of this systematic literature review was to describe the impact of PCV introduction to childhood national immunization programs worldwide on PCV-naive adult population. METHODS: A systematic literature search was performed using the PubMed database. The search was limited to articles written in English and published between January 2000 and February 2016. Studies evaluating pneumococcal disease rates in individuals over 5years of age were included. Independent extraction of articles was performed by the two authors. Search terms included: Pneumococcal conjugated vaccine, herd, indirect, adults, and pneumonia. RESULTS: Forty-nine articles meeting the selection criteria were identified, 39 regarding invasive pneumococcal disease (IPD, one on meningitis only), 8 regarding pneumonia, and 2 on both IPD and pneumonia. The majority of reports were from the US, UK and Canada. Considerable variability in the data sources, quality and completeness was observed. While most studies reported either statistically significant reduction or insignificant changes in IPD and pneumonia disease rates in adults following PCV nationwide implementation, few studies reported statistically significant increase in pneumococcal disease rates, these were mainly from countries with low PCV coverage rates and/or inadequate surveillance. CONCLUSION: Invasive pneumococcal diseases and pneumonia rates among the adult population decreased in most countries following PCV introduction into the NIP. This indirect effect on older population seems to be dependent on PCV coverage rates and time from PCV nationwide implementation. Adults >65years old seem to benefit the most from PCV introduction.
引用
- Tsaban G, Ben-Shimol S. Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature. Vaccine. 2017. PMID: 28449971. doi:10.1016/j.vaccine.2017.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。